二甲双胍与2型糖尿病合并或不合并心衰或肾功能不全患者的临床结局:SAVOR-TIMI 53试验观察
二甲双胍使用与主要复合终点风险无差异(HR 0.92,95%CI 0.76-1.11),但与全因死亡风险降低相关(HR 0.75,95%CI 0.59-0.95);在有既往心衰或中重度慢性肾脏病的患者中未见显著关联。
要点
- 二甲双胍使用与全因死亡风险降低相关(HR 0.75,95%CI 0.59-0.95)。
- 二甲双胍使用与心血管死亡、心梗或缺血性卒中复合终点无显著差异。
- 有既往心衰或中重度CKD者中,二甲双胍与上述终点无显著关联。
研究设计与样本
- 按试验期间是否曾使用二甲双胍分组,采用逆概率治疗加权Cox模型分析,并以生物标志物作为协变量。
- 敏感性分析包括倾向评分匹配和多变量Cox模型。
主要发现
- 8971例(74%)有二甲双胍暴露,1611例(13%)有既往心衰,1332例(11%)有至少中度慢性肾脏病(eGFR≤45 mL·min-1·1.73 m-2)。
- 二甲双胍使用与复合终点风险无差异(逆概率治疗加权HR 0.92,95%CI 0.76-1.11)。
- 二甲双胍使用与全因死亡风险降低相关(逆概率治疗加权HR 0.75,95%CI 0.59-0.95)。
- 在有既往心衰或中重度慢性肾脏病的患者中,二甲双胍使用与这些终点无显著关系。
临床怎么用
- 对于2型糖尿病合并高心血管风险的患者,二甲双胍使用可能与全因死亡风险降低相关。
- 在有既往心衰或中重度慢性肾脏病的患者中,二甲双胍与结局的关联不显著,临床决策需个体化。
局限性
- 本研究为事后分析,非随机对照设计,结论可能受残余混杂影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metformin is first-line therapy for type 2 diabetes mellitus, although its effects on the cardiovascular system are unproved. METHODS: In this post hoc analysis, patients in SAVOR-TIMI 53 (Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus) with baseline biomarker samples (n=12 156) were classified as ever versus never taking metformin during the trial period. Associations between metformin exposure and outcomes were estimated with inverse probability of treatment weighting Cox modeling for the composite end point of cardiovascular death, myocardial infarction, or ischemic stroke, as well as cardiovascular death and all-cause mortality, with biomarkers included as covariates. Additional sensitivity analyses included propensity score matching and Cox multivariable models. RESULTS: Of the 12 156 patients with baseline biomarker samples, 8971 (74%) had metformin exposure, 1611 (13%) had prior heart failure, and 1332 (11%) had at least moderate chronic kidney disease (estimated glomerular filtration rate ≤45 mL·min-1·1.73 m-2). Metformin use was associated with no difference in risk for the composite end point (hazard ratio for inverse probability of treatment weighting, 0.92 [95% CI, 0.76-1.11]) but lower risk of all-cause mortality (hazard ratio for inverse probability of treatment weighting, 0.75 [95% CI, 0.59-0.95]). There was no significant relationship between metformin use and these end points in patients with prior heart failure or moderate to severe chronic kidney disease. CONCLUSIONS: In a cohort of 12 156 patients with type 2 diabetes mellitus and high cardiovascular risk, metformin use was associated with lower rates of all-cause mortality, including after adjustment for clinical variables and biomarkers, but not lower rates of the composite end point of cardiovascular death, myocardial infarction, or ischemic stroke. This association was most apparent in patients without prior heart failure or moderate to severe chronic kidney disease. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01107886.
引用
- Bergmark BA, Bhatt DL, McGuire DK, et al. Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial. Circulation. 2019. PMID: 31362530. doi:10.1161/CIRCULATIONAHA.119.040144
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。